Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K, Varas L, Deronic A, Nyesiga B, Sundstedt A, Ljung L, Sakellariou C, Werchau D, Thagesson M, Gomez Jimenez D, Greiff L, Celander M, Smedenfors K, Rosén A, Bölükbas D, Carlsson F, Levin M, Säll A, von Schantz L, Lindstedt M, Ellmark P.
Hägerbrand K, et al. Among authors: nyesiga b.
J Immunother Cancer. 2022 Nov;10(11):e005018. doi: 10.1136/jitc-2022-005018.
J Immunother Cancer. 2022.
PMID: 36323431
Free PMC article.